Product Description
a Novel Nanomicellar Formulation of Cyclosporine A for the Treatment of Keratoconjunctivitis Sicca (Sourced from: https://pubmed.ncbi.nlm.nih.gov/31361655/)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Ophthalmic
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | Canada | Hong Kong | New Zealand | United States
Approved Indications: Conjunctivitis | Keratoconjunctivitis | Keratoconjunctivitis Sicca
Known Adverse Events: Hyperemia | Pain Unspecified
Company: Sun Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic: China
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Keratoconjunctivitis Sicca
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CTR20201772 | P3 |
Recruiting |
Keratoconjunctivitis Sicca |
None |